In all analyses shown in Figs. 1, 2, 3, 4, 5, 6, 7, the Hazard ratios for the specific outcomes of two sotagliflozin trials (SCORED and SOLOIST-HF), when included, were like to those of the other SGLT-2 inhibitors (empagliflozin, canagliflozin, dapagliflozin, ertugliflozin). This evidence concerns the gene SLC5A2 and hydrops fetalis.